;PMID: 3004922
;source_file_891.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..37]
;1)sentence:[e:44..198] = [t:44..198]
;2)section:[e:202..256] = [t:202..255]
;3)sentence:[e:260..644] = [t:260..644]
;4)sentence:[e:645..930] = [t:645..930]
;5)sentence:[e:931..1056] = [t:931..1056]
;6)sentence:[e:1057..1195] = [t:1057..1195]
;7)sentence:[e:1196..1321] = [t:1196..1321]
;8)sentence:[e:1322..1600] = [t:1322..1600]
;9)sentence:[e:1602..1709] = [t:1602..1709]
;10)sentence:[e:1710..1902] = [t:1710..1902]
;11)section:[e:1906..1950] = [t:1906..1949]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:0..38][t:0..37]
;ERROR_Section end mismatch[e:202..256][t:202..255]
;ERROR_Section end mismatch[e:1906..1950][t:1906..1949]
;Token/POS Errors
;ERROR_Token in entity file but not tree[37..38] .
;ERROR_Token in entity file but not tree[255..256] .
;ERROR_Token in entity file but not tree[1949..1950] ]

;section 0 Span:0..37
;Endocrinology. 1986 Apr;118(4):1583-9
(SEC
  (FRAG (NNP:[0..13] Endocrinology) (IN:[13..14] .) (CD:[15..19] 1986)
        (NNP:[20..23] Apr) (::[23..24] ;) (CD:[24..27] 118)
        (-LRB-:[27..28] -LRB-) (CD:[28..29] 4) (-RRB-:[29..30] -RRB-)
        (::[30..31] :) (CD:[31..35] 1583) (::[35..36] -) (CD:[36..37] 9)))

(ORPH .)

;sentence 1 Span:44..198
;Human parathyroid hormone inhibits renal 24-hydroxylase activity of 
;25-hydroxyvitamin D3 by a mechanism involving adenosine 3',5'-monophosphate
;in  rats.
;[50..69]:substance:"parathyroid hormone"
;[85..99]:cyp450:"24-hydroxylase"
;[113..133]:substance:"25-hydroxyvitamin D3"
;[159..188]:substance:"adenosine 3',5'-monophosphate"
(SENT
  (S-HLN
    (NP-SBJ (JJ:[44..49] Human)
       (JJ:[50..61] parathyroid) (NN:[62..69] hormone))
    (VP (VBZ:[70..78] inhibits)
      (NP
        (NP (JJ:[79..84] renal) (NN:[85..99] 24-hydroxylase)
            (NN:[100..108] activity))
        (PP (IN:[109..111] of)
          (NP (NN:[113..130] 25-hydroxyvitamin) (NN:[131..133] D3))))
      (PP-MNR (IN:[134..136] by)
        (NP
          (NP (DT:[137..138] a) (NN:[139..148] mechanism))
          (VP (VBG:[149..158] involving)
            (NP (NN:[159..168] adenosine) (NN:[169..188] 3',5'-monophosphate)))))
      (PP-LOC (IN:[189..191] in)
        (NP (NNS:[193..197] rats))))
    (.:[197..198] .)))
;ERROR_Orphan Text from Tree File[37..44] .

;section 2 Span:202..255
;Shigematsu T, Horiuchi N, Ogura Y, Miyahara T, Suda T
(SEC
  (FRAG (NNP:[202..212] Shigematsu) (NNP:[213..214] T) (,:[214..215] ,)
        (NNP:[216..224] Horiuchi) (NNP:[225..226] N) (,:[226..227] ,)
        (NNP:[228..233] Ogura) (NNP:[234..235] Y) (,:[235..236] ,)
        (NNP:[237..245] Miyahara) (NNP:[246..247] T) (,:[247..248] ,)
        (NNP:[249..253] Suda) (NNP:[254..255] T)))

(ORPH .)

;sentence 3 Span:260..644
;The in vivo effect of PTH on renal 24-hydroxylase activity of
;25-hydroxyvitamin  D3 (25OHD3) was examined in vitamin D-deficient
;thyroparathyroidectomized rats  by a recently developed sensitive in vitro
;assay of 25OHD3-hydroxylases using  rat kidney homogenates and by an in vivo
;assay measuring the accumulation of  tritiated metabolites in plasma 5 h
;after injection of 25OH[3H]D3.
;[282..285]:substance:"PTH"
;[295..309]:cyp450:"24-hydroxylase"
;[322..343]:substance:"25-hydroxyvitamin  D3"
;[345..351]:substance:"25OHD3"
;[369..378]:substance:"vitamin D"
;[473..492]:cyp450:"25OHD3-hydroxylases"
;[511..522]:substance:"homogenates"
;[588..599]:substance:"metabolites"
;[610..611]:quantitative-value:"5"
;[612..613]:quantitative-units:"h"
;[633..643]:substance:"25OH[3H]D3"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[260..263] The)
        (ADJP (FW:[264..266] in) (FW:[267..271] vivo))
        (NN:[272..278] effect))
      (PP (IN:[279..281] of)
        (NP (NN:[282..285] PTH)))
      (PP (IN:[286..288] on)
        (NP
          (NP (JJ:[289..294] renal) (NN:[295..309] 24-hydroxylase)
              (NN:[310..318] activity))
          (PP (IN:[319..321] of)
            (NP
              (NP (NN:[322..339] 25-hydroxyvitamin) (NN:[341..343] D3))
              (NP (-LRB-:[344..345] -LRB-) (NN:[345..351] 25OHD3)
                  (-RRB-:[351..352] -RRB-)))))))
    (VP (VBD:[353..356] was)
      (VP (VBN:[357..365] examined)
        (NP-1 (-NONE-:[365..365] *))
        (PP-LOC (IN:[366..368] in)
          (NP
            (ADJP
              (NML (NN:[369..376] vitamin) (NN:[377..378] D))
              (HYPH:[378..379] -) (JJ:[379..388] deficient))
            (VBN:[389..414] thyroparathyroidectomized) (NNS:[415..419] rats)))
        (PP-MNR
          (PP (IN:[421..423] by)
            (NP
              (NP
                (NP (DT:[424..425] a)
                  (ADJP (RB:[426..434] recently) (VBN:[435..444] developed))
                  (JJ:[445..454] sensitive)
                  (ADJP (FW:[455..457] in) (FW:[458..463] vitro))
                  (NN:[464..469] assay))
                (PP (IN:[470..472] of)
                  (NP (NNS:[473..492] 25OHD3-hydroxylases))))
              (VP (VBG:[493..498] using)
                (NP (NN:[500..503] rat) (NN:[504..510] kidney)
                    (NNS:[511..522] homogenates)))))
          (CC:[523..526] and)
          (PP (IN:[527..529] by)
            (NP
              (NP (DT:[530..532] an)
                (ADJP (FW:[533..535] in) (FW:[536..540] vivo))
                (NN:[541..546] assay))
              (VP (VBG:[547..556] measuring)
                (NP
                  (NP (DT:[557..560] the) (NN:[561..573] accumulation))
                  (PP (IN:[574..576] of)
                    (NP (JJ:[578..587] tritiated) (NNS:[588..599] metabolites))))
                (PP-LOC (IN:[600..602] in)
                  (NP (NN:[603..609] plasma)))
                (PP
                  (NP-ADV (CD:[610..611] 5) (NN:[612..613] h))
                  (IN:[614..619] after)
                  (NP
                    (NP (NN:[620..629] injection))
                    (PP (IN:[630..632] of)
                      (NP (NN:[633..643] 25OH-LSB-3H-RSB-D3)))))))))))
    (.:[643..644] .)))
;ERROR_Orphan Text from Tree File[255..260] .

;sentence 4 Span:645..930
;Infusion for  20 h of either human PTH-(1-34) (except at 800 pmol/h) or cAMP
;did not  significantly change the plasma levels of calcium and phosphorus
;compared with  those in thyroparathyroidectomized rats given 125 ng
;1,25-dihydroxyvitamin D3 to  induce renal 24-hydroxylase activity.
;[659..661]:quantitative-value:"20"
;[662..663]:quantitative-units:"h"
;[680..690]:substance:"PTH-(1-34)"
;[702..705]:quantitative-value:"800"
;[706..712]:quantitative-units:"pmol/h"
;[717..721]:substance:"cAMP"
;[773..780]:substance:"calcium"
;[785..795]:substance:"phosphorus"
;[857..860]:quantitative-value:"125"
;[861..863]:quantitative-units:"ng"
;[864..888]:substance:"1,25-dihydroxyvitamin D3"
;[906..920]:cyp450:"24-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[645..653] Infusion))
      (PP (IN:[654..657] for)
        (NP (CD:[659..661] 20) (NN:[662..663] h)))
      (PP (IN:[664..666] of)
        (NP (CC:[667..673] either)
          (NML
            (NML
              (ADJP-1 (JJ:[674..679] human))
              (NN:[680..690] PTH--LRB-1-34-RRB-)
              (PRN (-LRB-:[691..692] -LRB-)
                (PP (IN:[692..698] except)
                  (PP (IN:[699..701] at)
                    (NP
                      (NP (CD:[702..705] 800) (NN:[706..710] pmol))
                      (PP (SYM:[710..711] /)
                        (NP (NN:[711..712] h))))))
                (-RRB-:[712..713] -RRB-)))
            (CC:[714..716] or)
            (NML
              (ADJP-1 (-NONE-:[716..716] *P*))
              (NN:[717..721] cAMP))))))
    (VP (VBD:[722..725] did) (RB:[726..729] not)
      (ADVP (RB:[731..744] significantly))
      (VP (VB:[745..751] change)
        (NP
          (NP (DT:[752..755] the) (NN:[756..762] plasma) (NNS:[763..769] levels))
          (PP (IN:[770..772] of)
            (NP (NN:[773..780] calcium) (CC:[781..784] and)
                (NN:[785..795] phosphorus))))
        (S-ADV
          (NP-SBJ (-NONE-:[795..795] *))
          (VP (VBN:[796..804] compared)
            (NP (-NONE-:[804..804] *))
            (PP-CLR (IN:[805..809] with)
              (NP
                (NP (DT:[811..816] those))
                (PP (IN:[817..819] in)
                  (NP
                    (NP (VBN:[820..845] thyroparathyroidectomized)
                        (NNS:[846..850] rats))
                    (VP (VBN:[851..856] given)
                      (NP (-NONE-:[856..856] *))
                      (NP (CD:[857..860] 125) (NN:[861..863] ng)
                         (NN:[864..885] 1,25-dihydroxyvitamin)
                         (NN:[886..888] D3))
                      (S-PRP
                        (NP-SBJ (-NONE-:[888..888] *))
                        (VP (TO:[889..891] to)
                          (VP (VB:[893..899] induce)
                            (NP (JJ:[900..905] renal)
                                (NN:[906..920] 24-hydroxylase)
                                (NN:[921..929] activity))))))))))))))
    (.:[929..930] .)))

;sentence 5 Span:931..1056
;On the other hand, human PTH-(1-34)  markedly inhibited renal 24-hydroxylase
;activity and stimulated 1-hydroxylase  activity.
;[956..966]:substance:"PTH-(1-34)"
;[993..1007]:cyp450:"24-hydroxylase"
;[1032..1045]:cyp450:"1-hydroxylase"
(SENT
  (S
    (PP (IN:[931..933] On)
      (NP (DT:[934..937] the) (JJ:[938..943] other) (NN:[944..948] hand)))
    (,:[948..949] ,)
    (NP-SBJ (JJ:[950..955] human) (NN:[956..966] PTH--LRB-1-34-RRB-))
    (ADVP (RB:[968..976] markedly))
    (VP
      (VP (VBD:[977..986] inhibited)
        (NP (JJ:[987..992] renal) (NN:[993..1007] 24-hydroxylase)
            (NN:[1008..1016] activity)))
      (CC:[1017..1020] and)
      (VP (VBD:[1021..1031] stimulated)
        (NP (NN:[1032..1045] 1-hydroxylase) (NN:[1047..1055] activity))))
    (.:[1055..1056] .)))

;sentence 6 Span:1057..1195
;The effective concentration of human PTH-(1-34) was much lower for 
;inhibiting 24-hydroxylase than for stimulating 1-hydroxylase activity.
;[1094..1104]:substance:"PTH-(1-34)"
;[1136..1150]:cyp450:"24-hydroxylase"
;[1172..1185]:cyp450:"1-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1057..1060] The) (JJ:[1061..1070] effective)
          (NN:[1071..1084] concentration))
      (PP (IN:[1085..1087] of)
        (NP (JJ:[1088..1093] human) (NN:[1094..1104] PTH--LRB-1-34-RRB-))))
    (VP (VBD:[1105..1108] was)
      (ADJP-PRD
        (ADJP (RB:[1109..1113] much) (JJR:[1114..1119] lower))
        (PP-1 (-NONE-:[1119..1119] *ICH*)))
      (PP (IN:[1120..1123] for)
        (S-NOM
          (NP-SBJ (-NONE-:[1123..1123] *))
          (VP (VBG:[1125..1135] inhibiting)
            (NP (NN:[1136..1150] 24-hydroxylase)))))
      (PP-1 (IN:[1151..1155] than)
        (PP (IN:[1156..1159] for)
          (S-NOM
            (NP-SBJ (-NONE-:[1159..1159] *))
            (VP (VBG:[1160..1171] stimulating)
              (NP (NN:[1172..1185] 1-hydroxylase) (NN:[1186..1194] activity)))))))
    (.:[1194..1195] .)))

;sentence 7 Span:1196..1321
;Infusion  of less than 100 nmol/h cAMP similarly inhibited 24-hydroxylase
;activity without  enhancing 1-hydroxylase activity.
;[1209..1222]:quantitative-value:"less than 100"
;[1223..1229]:quantitative-units:"nmol/h"
;[1230..1234]:substance:"cAMP"
;[1255..1269]:cyp450:"24-hydroxylase"
;[1298..1311]:cyp450:"1-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1196..1204] Infusion))
      (PP (IN:[1206..1208] of)
        (NP
          (NML
            (NML
              (QP (JJR:[1209..1213] less) (IN:[1214..1218] than)
                  (CD:[1219..1222] 100))
              (NN:[1223..1227] nmol))
            (PP (SYM:[1227..1228] /)
              (NP (NN:[1228..1229] h))))
          (NN:[1230..1234] cAMP))))
    (ADVP (RB:[1235..1244] similarly))
    (VP (VBD:[1245..1254] inhibited)
      (NP (NN:[1255..1269] 24-hydroxylase) (NN:[1270..1278] activity))
      (PP (IN:[1279..1286] without)
        (S-NOM
          (NP-SBJ (-NONE-:[1286..1286] *))
          (VP (VBG:[1288..1297] enhancing)
            (NP (NN:[1298..1311] 1-hydroxylase) (NN:[1312..1320] activity))))))
    (.:[1320..1321] .)))

;sentence 8 Span:1322..1600
;Either theophylline (1.0 mumol/h) or a  submaximal dose (25 pmol/h) of human
;PTH-(1-34) alone inhibited 24-hydroxylase  activity only slightly, but the
;concomitant infusion of both chemicals markedly  inhibited 24-hydroxylase
;activity without stimulating 1-hydroxylase activity.
;[1329..1341]:substance:"theophylline"
;[1343..1346]:quantitative-value:"1.0"
;[1347..1354]:quantitative-units:"mumol/h"
;[1379..1381]:quantitative-value:"25"
;[1382..1388]:quantitative-units:"pmol/h"
;[1399..1409]:substance:"PTH-(1-34)"
;[1426..1440]:cyp450:"24-hydroxylase"
;[1503..1512]:substance:"chemicals"
;[1533..1547]:cyp450:"24-hydroxylase"
;[1577..1590]:cyp450:"1-hydroxylase"
(SENT
  (S
    (S
      (NP-SBJ (CC:[1322..1328] Either)
        (NP (NN:[1329..1341] theophylline)
          (PRN (-LRB-:[1342..1343] -LRB-)
            (NP
              (NP (CD:[1343..1346] 1.0) (NN:[1347..1352] mumol))
              (PP (SYM:[1352..1353] /)
                (NP (NN:[1353..1354] h))))
            (-RRB-:[1354..1355] -RRB-)))
        (CC:[1356..1358] or)
        (NP
          (NP (DT:[1359..1360] a) (JJ:[1362..1372] submaximal)
              (NN:[1373..1377] dose)
            (PRN (-LRB-:[1378..1379] -LRB-)
              (NP
                (NP (CD:[1379..1381] 25) (NN:[1382..1386] pmol))
                (PP (SYM:[1386..1387] /)
                  (NP (NN:[1387..1388] h))))
              (-RRB-:[1388..1389] -RRB-)))
          (PP (IN:[1390..1392] of)
            (NP
              (NP (JJ:[1393..1398] human) (NN:[1399..1409] PTH--LRB-1-34-RRB-))
              (ADVP (RB:[1410..1415] alone))))))
      (VP (VBD:[1416..1425] inhibited)
        (NP (NN:[1426..1440] 24-hydroxylase) (NN:[1442..1450] activity))
        (ADVP (RB:[1451..1455] only) (RB:[1456..1464] slightly))))
    (,:[1464..1465] ,) (CC:[1466..1469] but)
    (S
      (NP-SBJ
        (NP (DT:[1470..1473] the) (JJ:[1474..1485] concomitant)
            (NN:[1486..1494] infusion))
        (PP (IN:[1495..1497] of)
          (NP (DT:[1498..1502] both) (NNS:[1503..1512] chemicals))))
      (ADVP (RB:[1513..1521] markedly))
      (VP (VBD:[1523..1532] inhibited)
        (NP (NN:[1533..1547] 24-hydroxylase) (NN:[1548..1556] activity))
        (PP (IN:[1557..1564] without)
          (S-NOM
            (NP-SBJ (-NONE-:[1564..1564] *))
            (VP (VBG:[1565..1576] stimulating)
              (NP (NN:[1577..1590] 1-hydroxylase) (NN:[1591..1599] activity)))))))
    (.:[1599..1600] .)))

;sentence 9 Span:1602..1709
;These effects of human PTH-(1-34) and cAMP occurred similarly in both the in 
;vitro and the in vivo assays.
;[1625..1635]:substance:"PTH-(1-34)"
;[1640..1644]:substance:"cAMP"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1602..1607] These) (NNS:[1608..1615] effects))
      (PP (IN:[1616..1618] of)
        (NP
          (NP
            (ADJP-2 (JJ:[1619..1624] human))
            (NN:[1625..1635] PTH--LRB-1-34-RRB-))
          (CC:[1636..1639] and)
          (NP
            (ADJP-2 (-NONE-:[1639..1639] *P*))
            (NN:[1640..1644] cAMP)))))
    (VP (VBD:[1645..1653] occurred)
      (ADVP (RB:[1654..1663] similarly))
      (PP-LOC (IN:[1664..1666] in)
        (NP (CC:[1667..1671] both)
          (NP (DT:[1672..1675] the)
            (ADJP (FW:[1676..1678] in) (FW:[1680..1685] vitro))
            (NML-1 (-NONE-:[1685..1685] *P*)))
          (CC:[1686..1689] and)
          (NP (DT:[1690..1693] the)
            (ADJP (FW:[1694..1696] in) (FW:[1697..1701] vivo))
            (NML-1 (NNS:[1702..1708] assays))))))
    (.:[1708..1709] .)))

;sentence 10 Span:1710..1902
;The present study clearly indicates that besides  its well known action in
;stimulating 1-hydroxylase activity, PTH inhibits renal  25OHD3-24-hydroxylase
;activity by a mechanism involving cAMP.
;[1797..1810]:cyp450:"1-hydroxylase"
;[1821..1824]:substance:"PTH"
;[1841..1862]:cyp450:"25OHD3-24-hydroxylase"
;[1897..1901]:substance:"cAMP"
(SENT
  (S
    (NP-SBJ (DT:[1710..1713] The) (JJ:[1714..1721] present)
            (NN:[1722..1727] study))
    (ADVP (RB:[1728..1735] clearly))
    (VP (VBZ:[1736..1745] indicates)
      (SBAR (IN:[1746..1750] that)
        (S
          (PP (IN:[1751..1758] besides)
            (NP
              (NP (PRP$:[1760..1763] its)
                (ADJP (RB:[1764..1768] well) (VBN:[1769..1774] known))
                (NN:[1775..1781] action))
              (PP (IN:[1782..1784] in)
                (S-NOM
                  (NP-SBJ (-NONE-:[1784..1784] *))
                  (VP (VBG:[1785..1796] stimulating)
                    (NP (NN:[1797..1810] 1-hydroxylase)
                        (NN:[1811..1819] activity)))))))
          (,:[1819..1820] ,)
          (NP-SBJ (NN:[1821..1824] PTH))
          (VP (VBZ:[1825..1833] inhibits)
            (NP (JJ:[1834..1839] renal) (NN:[1841..1862] 25OHD3-24-hydroxylase)
                (NN:[1863..1871] activity))
            (PP-MNR (IN:[1872..1874] by)
              (NP
                (NP (DT:[1875..1876] a) (NN:[1877..1886] mechanism))
                (VP (VBG:[1887..1896] involving)
                  (NP (NN:[1897..1901] cAMP)))))))))
    (.:[1901..1902] .)))

;section 11 Span:1906..1949
;PMID: 3004922 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[1906..1910] PMID) (::[1910..1911] :) (CD:[1912..1919] 3004922)
        (-LRB-:[1920..1921] -LSB-) (NNP:[1921..1927] PubMed) (::[1928..1929] -)
        (NN:[1930..1937] indexed) (IN:[1938..1941] for)
        (NNP:[1942..1949] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[1949..EOF] ]

(ORPH -RSB-)
